Merger creates CNS biopharma worth $2.2 billion
Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company. The companies expect the transaction to generate significant value for stockholders of both companies, realising… Read More
